|
Market Closed -
NSE India S.E.
09:05:10 04/09/26 pm AEST
|
5-day change | 1st Jan Change | ||
| 1,899.00 INR | -0.89% |
|
-1.09% | +10.43% |
| 01/09 | Global pharma companies that have publicly announced Trump drug pricing agreements | RE |
| 01/09 | Trump announces new round of drug-pricing deals | RE |
| Market Cap | 4,556B 48.26B 41.53B 39.07B 35.69B 66.77B 66.95B 462B 179B 2,338B 181B 177B 7,531B | P/E 2027 * |
35x | P/E 2028 * | 29.7x |
|---|---|---|---|---|---|
| Enterprise Value | 4,286B 45.39B 39.06B 36.75B 33.57B 62.8B 62.97B 434B 169B 2,199B 170B 167B 7,084B | EV / Sales 2027 * |
6.58x | EV / Sales 2028 * | 5.79x |
| Free-Float |
44.39% | Yield 2027 * |
0.9% | Yield 2028 * | 1.05% |
| Markets | Quality | ||
|---|---|---|---|
NSE India S.E.
| SUNPHARMA | Delayed | |
Bombay S.E.
| SUNPHARMA | Delayed |
Last Transcript : Sun Pharmaceutical Industries Ltd.
| 1 day | -0.89% | ||
| 1 week | -1.09% | ||
| Current month | -4.32% | ||
| 1 month | -2.11% | ||
| 3 months | +6.55% | ||
| 6 months | +6.42% | ||
| Current year | +10.43% |
| 1 week | 1,895 |  | 1,984.8 |
| 1 month | 1,868.3 | | 1,984.8 |
| Current year | 1,583.7 | | 2,046.9 |
| 1 year | 1,548 | | 2,046.9 |
| 3 years | 1,068.35 | | 2,046.9 |
| 5 years | 733.7 | | 2,046.9 |
| 10 years | 312 | | 2,046.9 |
| Manager | Title | Age | Since |
|---|---|---|---|
Aalok Shanghvi
CEO | Chief Executive Officer | - | - |
| Chief Executive Officer | 59 | 01/09/2025 | |
| Director of Finance/CFO | 58 | 01/07/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | - | |
| Director/Board Member | 59 | 01/09/2025 | |
| Director/Board Member | 73 | 25/05/2018 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.89% | -1.09% | +19.16% | +67.77% | 48.26B | |
| -1.72% | -1.15% | +45.80% | +117.34% | 40.5B | |
| -0.70% | -2.70% | -10.84% | +11.79% | 11.85B | |
| -2.01% | -5.96% | +10.47% | +76.64% | 11.83B | |
| +2.31% | 0.00% | +26.67% | +153.33% | 9.36B | |
| +0.08% | -4.11% | +24.83% | +43.80% | 7.5B | |
| -1.67% | -0.35% | +41.04% | -11.59% | 7.37B | |
| -0.89% | -3.09% | +18.78% | +207.82% | 7.28B | |
| -0.16% | -2.36% | -46.14% | +16.28% | 5.19B | |
| -1.60% | -2.59% | +32.54% | +102.62% | 4.58B | |
| Average | -0.72% | -2.14% | +16.23% | +78.58% | 15.37B | |
| Weighted average by Cap. | -0.97% | -1.74% | +23.16% | +83.37% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 651B 6.9B 5.93B 5.58B 5.1B 9.54B 9.57B 65.97B 25.6B 334B 25.89B 25.33B 1,076B | 729B 7.72B 6.64B 6.25B 5.71B 10.68B 10.71B 73.87B 28.66B 374B 28.99B 28.36B 1,205B |
| Net income | 130B 1.37B 1.18B 1.11B 1.02B 1.9B 1.91B 13.14B 5.1B 66.53B 5.16B 5.04B 214B | 154B 1.63B 1.4B 1.32B 1.2B 2.25B 2.26B 15.57B 6.04B 78.83B 6.11B 5.98B 254B |
| Net Debt | -271B -2.87B -2.47B -2.32B -2.12B -3.97B -3.98B -27.43B -10.64B -139B -10.76B -10.53B -447B | -338B -3.58B -3.08B -2.9B -2.65B -4.96B -4.97B -34.29B -13.31B -174B -13.46B -13.17B -559B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 04/09/26 | INR 1,899.00 | -0.89% | 761,333 |
| 03/09/26 | INR 1,916.00 | -0.81% | 1,205,188 |
| 02/09/26 | INR 1,931.70 | +0.14% | 1,245,419 |
| 01/09/26 | INR 1,929.00 | -2.81% | 3,595,272 |
| 31/08/26 | INR 1,984.80 | +3.37% | 2,413,221 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SUNPHARMA Stock
Select your edition
All financial news and data tailored to specific country editions
